EurekAlert! Cancer Research

News Releases

Updates every hour. Last Updated: 13-Oct-2025 05:11 ET (13-Oct-2025 09:11 GMT/UTC)

8-Sep-2025

Lung cancer genetics study launches open-source data platform to research community

23andMe Research Institute
Business Announcement

At the 2025 World Conference on Lung Cancer in Barcelona, the 23andMe Research Institute, in collaboration with Troper Wojcicki Philanthropies and the health data software company Lifebit, introduced an open source platform that could help fast-track research discoveries through a powerful new cancer data repository. Access to this powerful new tool is FREE to qualified researchers.

8-Sep-2025

Resistance mutations and the blood–brain barrier: Key challenges in targeted treatment of brain metastatic non-small cell lung cancer

Compuscript Ltd
Peer-Reviewed Publication

https://doi.org/10.1016/j.apsb.2025.06.002

This new article publication from Acta Pharmaceutica Sinica B, discusses key challenges in targeted treatment of brain metastatic non-small cell lung cancer.

Journal: Acta Pharmaceutica Sinica B

8-Sep-2025

How does chemotherapy disrupt circadian rhythms?

Society for Neuroscience
Peer-Reviewed Publication

Using female mice, researchers find that a frequently used breast cancer treatment impairs molecular and behavioral measures of the primary biological clock found in the brain.

Journal: eNeuro
Funder: NIH/National Cancer Institute

8-Sep-2025

IU scientists reprogram cancer-protecting regulatory T cells to fight tumors

Indiana University
Peer-Reviewed Publication

A new method developed by IU School of Medicine researchers changes the behavior of immunosuppressive cells from cancer protectors to tumor fighters.

Journal: Science Immunology

8-Sep-2025

Cancer cells can use backup routes to fuel their growth

Van Andel Research Institute
Peer-Reviewed Publication

A new study by Van Andel Institute scientists suggest that the routes cancer cells use to process different nutrients deeply influence cell behavior. They discovered an alternate, or non-canonical, path by which cancer cells convert a ketone called β-hydroxybutyrate (β-OHB) into acetyl-CoA, an essential metabolic building block for fatty acids and cholesterol that supports cell proliferation. The findings, published today in the journal Nature Metabolism, could reshape how the relationship between diet and cancer is viewed.

Journal: Nature Metabolism
Funder: NIH/National Cancer Institute, NIH/National Cancer Institute, NIH/National Institute of Allergy and Infectious Diseases, Van Andel Institute Metabolism & Nutrition (MeNu) Program, Canadian Institutes of Health Research

8-Sep-2025

Tarlatamab with anti-PD-L1 as first-line maintenance after chemo-immunotherapy for ES-SCLC demonstrates acceptable safety profile and unprecedented overall survival

International Association for the Study of Lung Cancer
Reports and Proceedings

Clinical data presented today demonstrates the combination of tarlatamab with anti-PD-L1 therapy as first-line maintenance has an acceptable safety profile and resulted in unprecedented overall survival in patients with extensive-stage small cell lung cancer (ES-SCLC).

8-Sep-2025

Moffitt develops first genetically engineered cancer model in naked mole rats

H. Lee Moffitt Cancer Center & Research Institute
Peer-Reviewed Publication

Researchers at Moffitt Cancer Center have created the first genetically engineered model of lung cancer in naked mole rats, a species long thought to be resistant to cancer. The findings, published in Cancer Discovery, shed light on how cancer begins in this unusual rodent and may reveal new parallels to tumor development in humans.

Journal: Cancer Discovery
Funder: NIH/National Institutes of Health

8-Sep-2025

First-ever clinical trial demonstrates safety, molecular readout and promise of pre- and post-surgery immunotherapy combination for patients with operable mesothelioma

Johns Hopkins Medicine
Peer-Reviewed Publication

A novel treatment approach using combination immunotherapy before and after surgery shows promise for patients with operable mesothelioma, according to a new study led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy.

Journal: Nature Medicine
Funder: Department of Defense Congressionally Directed Medical Research Program, Johns Hopkins Kimmel Cancer Center NCI, U.S. Food and Drug Administration, NIH/National Institutes of Health, Bloomberg~Kimmel Institute for Cancer Immunotherapy, ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center, Robyn Adler Fellowship Award, Commonwealth Foundation, Mark Foundation For Cancer Research, Florence Lomax Eley Fund

8-Sep-2025

‘Rogue’ DNA rings reveal earliest clues to deadly brain cancer’s growth

Queen Mary University of London
Peer-Reviewed Publication

An international team of scientists has revealed how rogue rings of DNA that float outside of our chromosomes – known as extrachromosomal DNA, or ecDNA – can drive the growth of a large proportion of glioblastomas, the most common and aggressive adult brain cancer. The discovery could open the door to much-needed new approaches to diagnose glioblastoma early, track its progress and treat it more effectively.

Journal: Cancer Discovery
Funder: Francis Crick Institute, Cancer Research UK, NIH/National Cancer Institute

8-Sep-2025

Clinical study deepens understanding of mesothelioma and opens the door to potential treatment options

Georgetown University Medical Center
Peer-Reviewed Publication

People with operable diffuse pleural mesothelioma may benefit from immunotherapy before and after surgery, based on results of a clinical trial exploring the sequence of treatment and the role of surgery for this difficult to treat cancer.

Journal: Nature Medicine
Funder: The trial was sponsored by Bristol Myers Squibb.